Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Research & Development (2019 - 2025)

Allogene Therapeutics' Research & Development history spans 7 years, with the latest figure at $31.2 million for Q3 2025.

  • For Q3 2025, Research & Development fell 30.3% year-over-year to $31.2 million; the TTM value through Sep 2025 reached $166.5 million, down 17.57%, while the annual FY2024 figure was $192.3 million, 20.84% down from the prior year.
  • Research & Development for Q3 2025 was $31.2 million at Allogene Therapeutics, down from $40.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $80.2 million in Q1 2023 and bottomed at $31.2 million in Q3 2025.
  • The 5-year median for Research & Development is $54.0 million (2021), against an average of $54.4 million.
  • The largest annual shift saw Research & Development surged 39.71% in 2022 before it plummeted 34.87% in 2024.
  • A 5-year view of Research & Development shows it stood at $54.0 million in 2021, then soared by 39.71% to $75.4 million in 2022, then fell by 27.52% to $54.7 million in 2023, then dropped by 17.73% to $45.0 million in 2024, then crashed by 30.7% to $31.2 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Research & Development are $31.2 million (Q3 2025), $40.2 million (Q2 2025), and $50.2 million (Q1 2025).